Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.

Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW.

Mod Pathol. 2007 Jul;20(7):779-87.

2.

[Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].

Vasil'ev EV, Rumiantsev PO, Saenko VA, Il'in AA, Poliakova EIu, Nemtsova MV, Zaletaev DV.

Mol Biol (Mosk). 2004 Jul-Aug;38(4):642-53. Russian.

PMID:
15456136
3.

Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.

Durand S, Ferraro-Peyret C, Joufre M, Chave A, Borson-Chazot F, Selmi-Ruby S, Rousset B.

Endocr Relat Cancer. 2009 Jun;16(2):467-81. doi: 10.1677/ERC-08-0081.

4.

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.

Clin Endocrinol (Oxf). 2006 Jan;64(1):105-9.

PMID:
16402937
5.

Oncogenic alterations in papillary thyroid cancers of young patients.

Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A.

Thyroid. 2012 Jan;22(1):17-26. doi: 10.1089/thy.2011.0215.

PMID:
22150560
6.

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.

Cancer Res. 2003 Aug 1;63(15):4561-7.

7.

Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.

Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A.

Neuro Endocrinol Lett. 2007 Aug;28(4):351-9.

PMID:
17693984
8.

[BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].

Zhu XL, Zhou XY, Zhu XZ.

Zhonghua Bing Li Xue Za Zhi. 2005 May;34(5):270-4. Chinese.

PMID:
16181547
9.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

10.

Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW.

World J Surg. 2008 May;32(5):722-8. doi: 10.1007/s00268-007-9431-6.

PMID:
18235983
11.

[Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].

Rumiantsev PO, Zaletaev DV, Vasil'ev EV, Saenko VA, Il'in AA, Rumiantseva UV, Abrosimov AIu, Medvedev VS.

Vopr Onkol. 2006;52(2):145-9. Russian.

PMID:
17195637
12.

RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).

Nakazawa T, Kondo T, Kobayashi Y, Takamura N, Murata S, Kameyama K, Muramatsu A, Ito K, Kobayashi M, Katoh R.

Cancer. 2005 Sep 1;104(5):943-51.

13.

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.

Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S.

Endocr J. 2011;58(5):381-93.

14.

Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.

Mechler C, Bounacer A, Suarez H, Saint Frison M, Magois C, Aillet G, Gaulier A.

Br J Cancer. 2001 Dec 14;85(12):1831-7.

15.
16.

The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.

Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG, Fugazzola L.

Clin Endocrinol (Oxf). 2010 May;72(5):702-8. doi: 10.1111/j.1365-2265.2009.03699.x.

PMID:
20447069
17.

[The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].

Wang P, Wang YG, Zhao WJ, Fu YD, Wang L, Wang F, Zhao SH.

Zhonghua Nei Ke Za Zhi. 2012 Dec;51(12):987-91. Chinese.

PMID:
23327964
18.

Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.

Guerra A, Zeppa P, Bifulco M, Vitale M.

Thyroid. 2014 Feb;24(2):254-9. doi: 10.1089/thy.2013.0235.

PMID:
23806056
19.

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.

Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6.

PMID:
16181240
20.

RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.

Mochizuki K, Kondo T, Nakazawa T, Iwashina M, Kawasaki T, Nakamura N, Yamane T, Murata S, Ito K, Kameyama K, Kobayashi M, Katoh R.

Histopathology. 2010 Sep;57(3):444-50. doi: 10.1111/j.1365-2559.2010.03646.x.

PMID:
20840674

Supplemental Content

Support Center